Oncotelic Therapeutics, Inc. (OTLC) IPO - S-1 Filing, Stock & Insider Activity
Oncotelic Therapeutics, Inc. IPO - Status & S-1 Filing
- Ticker: OTLC
- Status: Registered - S-1 filed with the SEC
- S-1 filed: 2025-11-21
- Expected price range: not yet disclosed (set in a later S-1/A or pricing amendment)
- SEC CIK: 0000908259 · View the S-1 on SEC EDGAR →
Track every registration update on the InsiderAlpha IPO tracker.
Last SEC filing
Oncotelic Therapeutics, Inc. (OTLC) has filed 10 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-23. Insiders disclosed 7 open-market purchases totaling $38K. 3 Form 8-K material event filings were reported by OTLC in the last 90 days. InsiderAlpha tracks every OTLC SEC filing - Form 4, Form 144, and 8-K - in real time, including Rule 10b5-1 plan detection.
About Oncotelic Therapeutics, Inc. (OTLC)
Oncotelic Therapeutics, Inc. trades under the ticker OTLC. InsiderAlpha tracks 14 primary SEC Form 4 filings from 6 reporting insiders for OTLC since 2024, sourced directly from SEC EDGAR.
| Sector | Health Care insider trading |
|---|---|
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
| SEC CIK | 0000908259 |
90-Day SEC Filing Activity
| Insider purchases (90d) | 7 ($38K) |
|---|---|
| Form 4 filings (90d) | 10 |
| Form 8-K filings (90d) | 3 |
| Latest Form 4 filing | 2026-07-23 |
Recent OTLC Insider Transactions (Form 4)
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Vuong Trieu | CHAIRMAN AND CEO | P - Open-market purchase | 240.0K | $0.04 | $10K | SEC | |
| Vuong Trieu | CHAIRMAN AND CEO | P - Open-market purchase | 115.0K | $0.04 | $5K | SEC | |
| Vuong Trieu | CHAIRMAN AND CEO | P - Open-market purchase | 75.0K | $0.04 | $3K | SEC | |
| Amit B. Shah | CFO | P - Open-market purchase | 20.0K | $0.05 | $1K | SEC | |
| Vuong Trieu | CHAIRMAN AND CEO | P - Open-market purchase | 65.0K | $0.04 | $3K | SEC | |
| Vuong Trieu | CHAIRMAN AND CEO | P - Open-market purchase | 239.8K | $0.04 | $11K | SEC | |
| Vuong Trieu | CHAIRMAN AND CEO | P - Open-market purchase | 96.0K | $0.04 | $4K | SEC | |
| Vuong Trieu | CHAIRMAN AND CEO | P - Open-market purchase | 104.0K | $0.01 | $520 | SEC | |
| Vuong Trieu | CHAIRMAN AND CEO | P - Open-market purchase | 1 | $0.01 | $0 | SEC | |
| Vuong Trieu | CHAIRMAN AND CEO | P - Open-market purchase | 94.7K | $0.01 | $474 | SEC | |
| Vuong Trieu | CHAIRMAN AND CEO | P - Open-market purchase | 298.5K | $0.03 | $9K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Oncotelic Therapeutics, Inc. (OTLC). Updated in real time as new filings are submitted to the SEC.
Most-Active OTLC Insiders - Last 90 Days
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Vuong Trieu | 7 | $37K |
| Amit B. Shah | 2 | $1K |
| Anthony E. Maida III | 1 | - |
| Saran Saund | 1 | - |
| Steven W. King | 1 | - |
Recent OTLC Form 8-K Material Events
- - Item 8.01, 9.01 [SEC]
- - Item 3.02, 5.02, 9.01 [SEC]
- - Item 1.01, 2.03, 3.02, 9.01 [SEC]
- - Item 1.01, 2.01, 3.02, 9.01 [SEC]
- - Item 8.01, 9.01 · Other · neutral [SEC]
Oncotelic Therapeutics issued a press release on April 16, 2026 announcing the company's annual results and corporate updates. The filing provides no specific financial data, operational metrics, or material developments in the 8-K itself, with details relegated to the attached p
Recent Insider Filings
- - Seymour Howard Fein (CRO/CMO)
- - Steven W. King (Director)
- - Anthony E. Maida III (DIRECTOR AND CMO - TRANS. MED.)
- - Saran Saund (CBO)
- - Amit B. Shah (CFO)
Form 4 Transaction Code Reference
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in OTLC insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
OTLC Insider Trading - FAQ
- What is the latest insider trade for OTLC?
- Oncotelic Therapeutics, Inc. (OTLC) had 10 insider filings in the last 90 days, with the most recent on 2026-07-23. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
- How many insiders are buying OTLC stock?
- 7 insider purchases of OTLC were filed in the last 90 days, totaling $38K.
- How many insiders are selling OTLC stock?
- 0 insider sales of OTLC were filed in the last 90 days.
- Where can I see OTLC SEC filings (Form 4, 10-K, 10-Q, 8-K)?
- This page tracks OTLC Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care Companies with Insider Activity
Other companies in the InsiderAlpha index with a significant SEC Form 4 insider-trading footprint:
- $PEPG PepGen Inc.
- $PHGE BiomX Inc.
- $PLSE PULSE BIOSCIENCES, INC.
- $PMHS Polomar Health Services, Inc.
- $PRCT PROCEPT BioRobotics Corp
- $PRLD Prelude Therapeutics Inc
- $PRME Prime Medicine, Inc.
- $PSTV PLUS THERAPEUTICS, INC.
- $PTN PALATIN TECHNOLOGIES INC
- $QTI QT IMAGING HOLDINGS, INC.
Related Companies - Recent Insider Activity
- UNITED THERAPEUTICS Corp (UTHR)
- Liquidia Corp (LQDA)
- BeOne Medicines Ltd. (ONC)
- PERRIGO Co plc (PRGO)
- Processa Pharmaceuticals, Inc. (PCSA)
- Nuvalent, Inc. (NUVL)
- CYTOKINETICS INC (CYTK)
- Elanco Animal Health Inc (ELAN)
- Avalo Therapeutics, Inc. (AVTX)
- NATURES SUNSHINE PRODUCTS INC (NATR)
Learn More
- What is SEC Form 4?
- How to read insider buying signals
- Rule 10b5-1 trading plans explained
- The cluster buying signal
Open the live OTLC dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.